Physician profile
Ryan Mansi
NPI 1558986174
$4,596.72
in general payments reported to CMS, 2019-2025
31 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 92% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $280 · 2023: $1,041 · 2024: $1,433 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,135.63 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $777.42 | 2023-2025 | Xcopri |
| Emd Serono, INC. | $575.72 | 2021-2025 | Mavenclad |
| Ucb, INC. | $555.91 | 2023-2025 | Fintepla, Briviact, Rystiggo |
| Abbvie INC. | $431.72 | 2023-2025 | |
| Lundbeck LLC | $412.20 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $222.45 | 2021-2024 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $184.97 | 2022-2025 | |
| Biogen, INC. | $172.57 | 2022-2025 | Tysabri, Vumerity |
| Axsome Therapeutics, INC. | $120.75 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $120.26 | 2023-2025 | Ultomiris |
| Eisai INC. | $113.95 | 2024-2025 | |
| Neurelis, INC. | $113.18 | 2024-2025 | Valtoco |
| Lilly USA, LLC | $105.28 | 2024-2025 | Kisunla, Amyvid |
| Amneal Pharmaceuticals LLC | $103.21 | 2023-2024 | Lyvispah, Rytary |
| Octapharma USA, INC. | $92.92 | 2024-2025 | Panzyga |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $56.79 | 2024 | |
| Argenx US, INC. | $46.12 | 2024-2025 | Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company LTD. | $45.69 | 2022 | |
| Scilex Pharmaceuticals INC. | $44.90 | 2025 | |
| Genentech USA, INC. | $40.34 | 2023-2024 | Ocrevus |
| Avanir Pharmaceuticals, INC. | $38.68 | 2021-2022 | |
| Amylyx Pharmaceuticals, INC. | $36.61 | 2023 | Relyvrio |
| Janssen Pharmaceuticals, INC | $33.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.81 | 2024 | Nuedexta |
| Amgen INC. | $24.79 | 2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $17.97 | 2025 | Hyqvia |
| Cycle Pharmaceuticals INC | $17.38 | 2025 | Tascenso Odt |
| Kedrion Biopharma, INC. | $17.23 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Upsher-Smith Laboratories LLC | $15.80 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.80 | 2023 | Horizant |
| Alnylam Pharmaceuticals INC. | $14.40 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mansi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.